Intergroupe Francophone De Cancerologie Thoracique

This study tests whether giving immunotherapy with chemotherapy before radiation can help elderly or less fit patients with stage III lung cancer live longer without their cancer getting worse. About 152 participants will receive either the new combination or standard care. The g…

This study tests a drug called ivonescimab in 38 people with pleural mesothelioma whose cancer returned after immunotherapy and chemotherapy. The drug works by blocking two pathways that help tumors grow. The goal is to see if it can stop the cancer from getting worse for at leas…

This study compares the targeted drug tepotinib to standard treatments in 133 people with advanced MET-mutated non-small cell lung cancer whose disease has worsened after initial therapy. Tepotinib is a pill that blocks cancer growth and has shown a 50% response rate in earlier s…

This Phase 3 trial compares the experimental drug tarlatamab to standard chemotherapy in 129 adults with advanced neuroendocrine carcinoma (a rare cancer of the lung or digestive system) that has worsened after prior treatment. The main goal is to see if tarlatamab helps people l…